Angewandte Chemie International Edition · 2014 · 123 citations · 13 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryNeurodegenerationNeuropharmacologyMulti-target Drug DesignNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionNeuroprotective PharmacologyPharmacokinetics In DementiaAlzheimer Disease NeuroprotectionAlzheimer's Disease PharmacokineticsBrain PermeabilityCell-based AssaysCell-based Pharmacological AssaysDementia Drug DevelopmentNeuroprotective AgentsNeuroprotective Drug Development
Cumulative evidence strongly supports that the amyloid and tau hypotheses are not mutually exclusive, but concomitantly contribute to neurodegeneration in Alzheimer's disease (AD). Thus, the development of multitarget drugs which are involved in both pathways might represent a promising therapeutic strategy. Accordingly, reported here in is the discovery of 6-amino-4-phenyl-3,4-dihydro-1,3,5-triazin-2(1H)-ones as the first class of molecules able to simultaneously modulate BACE-1 and GSK-3β. Notably, one triazinone showed well-balanced in vitro potencies against the two enzymes (IC50 of (18.03±0.01) μM and (14.67±0.78) μM for BACE-1 and GSK-3β, respectively). In cell-based assays, it displayed effective neuroprotective and neurogenic activities and no neurotoxicity. It also showed good brain permeability in a preliminary pharmacokinetic assessment in mice. Overall, triazinones might represent a promising starting point towards high quality lead compounds with an AD-modifying potential.
13